Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A. Khattak, Jason J. Luke, Georgina V. Long, et al.
European Journal of Cancer (2022) Vol. 176, pp. 207-217
Open Access | Times Cited: 14

Showing 14 citing articles:

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C. Pavlick, Charlotte E. Ariyan, Elizabeth I. Buchbinder, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e006947-e006947
Open Access | Times Cited: 23
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason J. Luke, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007501-e007501
Open Access | Times Cited: 6
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kiciński, Mario Mandalà, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1202-1212
Closed Access | Times Cited: 5
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
Karen Abboud, Godsfavour Umoru, Abdullah Esmail, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1433-1433
Open Access | Times Cited: 13
Adjuvant therapy for stage II melanoma: the need for further studies
Rebecca Lee, Mario Mandalà, Georgina V. Long, et al.
European Journal of Cancer (2023) Vol. 189, pp. 112914-112914
Open Access | Times Cited: 12
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial
John M. Kirkwood, Peter Mohr, Christoph Höeller, et al.
European Journal of Cancer (2025), pp. 115371-115371
Open Access
Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment
Piotr Rutkowski, Mario Mandalà
European Journal of Surgical Oncology (2024) Vol. 50, Iss. 3, pp. 107969-107969
Closed Access | Times Cited: 3
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma
Jason J. Luke, Georgina V Long, Caroline Robert, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114146-114146
Open Access | Times Cited: 3
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
Katharina C. Kähler, Svea Hüning, D. Nashan, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 13, pp. 11705-11718
Open Access | Times Cited: 2
Harold Gillies, pioneer of modern plastic surgery, and Donald Morton, pioneer of modern surgical oncology: Master problem-solvers and surgical role models
John F. Thompson
Journal of Plastic Reconstructive & Aesthetic Surgery (2023) Vol. 87, pp. 24-32
Open Access | Times Cited: 1
Excess Weight leads to a better Health-Related Quality of Life in patients with Cancer
Yiding Dai, Yong Zhang, Qingsong Yu, et al.
Research Square (Research Square) (2024)
Open Access
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Katharina C. Kähler, Ralf Gutzmer, Yenny Angela, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access
Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
Toni Maria Janke, Laura Moysig, Christine Blome, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 151, Iss. 1
Open Access
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review
Sofia Georgopoulou, Joanne Droney, P.P. Jaganathan, et al.
Cancer Treatment Reviews (2024) Vol. 135, pp. 102862-102862
Open Access
Page 1

Scroll to top